IL17A and psoriasis: There were also no significant differences in the rate of COVID-19 hospitalization between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics in the children group (RR: 38.50; 95% CI: 0.99-1496.08; P = 0.05) and the NA group (RR: 0.39; 95% CI: 0.08-1.83; P = 0.23), respectively (Figure 4B).